Comparative Efficacy of Aliskiren/Valsartan vs Valsartan in Nocturnal Dipper and Nondipper Hypertensive Patients: A Pooled Analysis

Journal of Clinical Hypertension

Volumn 14, Issue 5, 2012, Pages 299-306

  Giles, Thomas D ^a   Alessi, Thomas ^b   Purkayastha, Das ^b   Zappe, Dion ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN PLUS VALSARTAN; PLACEBO; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BACKACHE; BLOOD PRESSURE MONITORING; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NONCARDIAC CHEST PAIN; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINOPHARYNGITIS; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VERTIGO;

ADULT; AGED; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84860346383     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00608.x     Document Type: Article

References (33)

1. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219-1230.
2. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011;342:d3621.
3. National Institute of Health and Clinical Excellence (NICE). Hypertension. Clinical management of primary hypertension in adults. NICE clinical guideline 127. August 2011.
4. Ghuman N, Campbell P, White WB. Role of ambulatory and home blood pressure recording in clinical practice. Curr Cardiol Rep. 2009;11:414-421.
5. Rafey M. Beyond office sphygmomanometry: ways to better assess blood pressure. Cleve Clin J Med. 2009;76:657-662.
6. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161.
7. Dolan E, Stanton AV, Thom S, et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27:876-885.
8. Pickering TG, White WB, Giles TD, et al. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4:56-61.
9. Giles TD, Oparil S, Ofili EO, et al. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Blood Press Monit. 2011;16:87-95.
10. White WB. Ambulatory blood pressure monitoring: dippers compared with non-dippers. Blood Press Monit. 2000;5(Suppl 1):S17-S23.
11. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm. 2007;8(Suppl B):34-39.
12. Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011;58:1165-1173.
13. Jensen LW, Pedersen EB. Nocturnal blood pressure and relation to vasoactive hormones and renal function in hypertension and chronic renal failure. Blood Press. 1997;6:332-342.
14. Vijayaraghavan K, Deedwania P. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin. 2011;29:137-156.
15. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-229.
16. NCT00219180. Clinical study to evaluate efficacy and safety of aliskiren (150mg & 300mg) administered alone and in combo with valsartan (160mg and 320mg) in patients with high blood pressure. ClinicalTrials.gov. Accessed October 10, 2011.
17. NCT00809926: 8 weeks study to evaluate the efficacy and safety of valsartan in combination with aliskiren compared to valsartan alone in patients with stage 2 hypertension (VANTAGE). ClinicalTrials.gov. Accessed October 10, 2011.
18. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990;81:528-536.
19. Polónia J, Diogo D, Caupers P, Damasceno A. Influence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt diet. J Cardiovasc Pharmacol. 2003;42:98-104.
20. Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005;23:1913-1922.
21. Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens. 2008;26:583-588.
22. Kario K. Proposal of RAS-diuretic vs RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure. J Am Soc Hypertens. 2010;4:215-218.
23. Fukuda M, Wakamatsu-Yamanaka T, Mizuno M, et al. Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption. Am J Physiol Renal Physiol. 2011;301(5):F953-957.
24. Hermida RC, Ayala DE, Mojón A, et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011;28:601-610.
25. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
26. Yarows SA, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther. 2008;25:1288-1302.
27. Geiger H, Barranco E, Gorostidi M, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens (Greenwich). 2009;11:324-332.
28. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Curr Med Res Opin. 2010;26:2841-2849.
29. Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685-1691.
30. Malacco E, Piazza S, Scandiani L, Zoppi A. Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Adv Ther. 2004;21:149-161.
31. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010;28:2177-2183.
32. de la Sierra A, Segura J, Gorostidi M, et al. Diurnal blood pressure variation, risk categories and antihypertensive treatment. Hypertens Res. 2010;33:767-771.
33. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12, 942 patients. J Clin Hypertens (Greenwich). 2011;13:506-516.